New York, January 6, 2026, 13:08 (EST) — Regular session
- Beam Therapeutics shares were up about 5% at $28.24 in midday trading after touching $30.49.
- BofA analyst Alec Stranahan raised his target price to $45 from $43 and kept a buy rating, Futu News reported.
- A fresh SEC filing showed an automatic insider sale tied to tax withholding under a pre-arranged trading plan.
Beam Therapeutics (BEAM.O) shares rose about 5% to $28.24 by early afternoon on Tuesday after Bank of America raised its price target to $45 from $43 and kept a buy rating, according to a note carried by Futu News. The stock opened at $26.64, hit a session high of $30.49 and traded about 1.1 million shares.
The move mattered because traders were pushing up gene-editing stocks broadly, a space that often moves on analyst calls and conference headlines early in the year. CRISPR Therapeutics (CRSP.O) rose about 4.4%, Intellia Therapeutics (NTLA.O) gained about 2.1%, Prime Medicine (PRME.O) added about 2.7% and Editas Medicine (EDIT.O) was up about 1.5%.
Beam is developing precision genetic medicines using base editing, a form of gene editing aimed at making single-letter changes in DNA without cutting both strands. The Cambridge, Massachusetts-based company’s pipeline includes programs in diseases such as sickle cell disease and alpha-1 antitrypsin deficiency, a genetic disorder that can damage the lungs and liver.
Investors are also looking ahead to the J.P. Morgan Healthcare Conference, a major annual forum for biotech updates. Beam said Chief Executive John Evans is scheduled to present on Jan. 13 at 5:15 p.m. PT in San Francisco, with a webcast available on the company’s website.
A Form 4 filing on Monday showed Chief Legal Officer Christine Bellon sold 1,254 shares on Dec. 31 at $27.10 in an automatic transaction tied to restricted stock vesting. The filing said the shares were sold “to cover tax withholding obligations” under a Rule 10b5-1 plan — a pre-arranged trading program that lets insiders set trades in advance.
But Beam remains a development-stage biotech with no approved products, leaving the stock sensitive to trial safety signals, regulatory feedback and timelines that can slip. Any surprise dilution or a setback in clinical work can quickly reverse sentiment.
